An Australian study provides the first demonstration that an ionophore, a compound that transports metal ions across cell membranes, can elicit rapid and pronounced improvement in neuropathology and cognitive function in mouse models of Alzheimer's. This is particularly encouraging because of its significance regarding PBT2, a new medication already in clinical trials.

Flurizan Fails to Achieve Significance on Either Co-Primary Endpoint; Its Developer, Myriad Genetics, Has Decided to Discontinue Its Development of Flurizan.

The "ECog" Everyday Cognition Test quickly and easily identifies mild functional problems in older adults. It could be extremely useful in primary-care settings, where dementia and its early warning signs are frequently missed.

SEE VIDEO

Scientists have puzzled over beta-amyloid's apparent roll in the development and progression of Alzheimer's for years. Two new amyloid studies just put another piece into place.

An experimental Alzheimer's medication called bapineuzumab just finished an 18-month trial. It appeared to have clinical activity in treating Alzheimer’s, particularly for the many patients not carrying genes associated with Alzheimer's.

PredictAD launched an impressive research collaboration aimed at developing new diagnostic procedures for patients with Alzheimer’s. Funded by the European Union, it includes a consortium of leading research European institutions.

Yale University researchers blocked a common immune system response. The result? It cleared up plaques associated with Alzheimer’s. Treated mice recovered some lost memory.

Chronic bacterial infections and associated viral infections are emerging as key players in Alzheimer's. Treating these with available medications may result in regression and even prevention of Alzheimer's.

Physical chemists show precisely how a minor, seemingly inconsequential mutation results in unexpected changes in a very delicate chemical balance, creating the build-up of the toxic by-products behind Alzheimer's.

SEE VIDEO

In a new study, long-term use of ibuprofen and other drugs commonly used for aches and pains was associated with a lower risk of Alzheimer’s disease.